Cytokine regulation of immune response in patients with a brain tumor or injury

Mkhoyan, G.; Ter-Pogossian, Z. R.; Gasparyan, Mari; Dzhagatspanyan, N. G.; Hovhannesyan, G. G.

doi:10.1134/s1819712408040223

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to these findings, Mkhoyan et al [25] found similar TNFα levels in patients and in healthy controls. The pro-inflammatory cytokine TNFα, has cytotoxic and anti-tumorigenic effects.…”

Section: Discussionmentioning

confidence: 47%

Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy

Demirci¹,

Yaman²,

Büyükberber³

et al. 2012

International Immunopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 47%

Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy

Demirci¹,

Yaman²,

Büyükberber³

et al. 2012

International Immunopharmacology

View full text Add to dashboard Cite

“…In addition, it has been shown that brain tumours and peritumoral regions express IFN-γ mRNA (Nitta et al, 1994). More recently, elevated IFN-γ serum concentrations have been reported in brain tumour patients compared to healthy donors (Mkhoyan et al, 2008). Considering these different points, we decided to investigate the immunoregulatory properties of resting or IFN-γ-treated GBM cells.…”

Section: Discussionmentioning

confidence: 99%

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions

Avril¹,

Saïkali²,

Vauléon³

et al. 2010

Journal of Neuroimmunology

View full text Add to dashboard Cite

Immunotherapy is a promising new treatment for patients suffering from glioma, in particular glioblastoma multiforme (GBM). However, tumour cells use different mechanisms to escape the immune responses induced by the treatment. As many other tumours, gliomas express or secrete several immunosuppressive molecules that regulate immune cell functions. In this study, we first analysed FasL, HLA-G, IDO, PDL-1 and TGF-beta1, -beta2 and -beta3 expression by transcriptomic microarray analysis in a series of 20 GBM samples and found respectively 15%, 60%, 85%, 30%, 70%, 80% and 35% of positive specimens. mRNA expression was then confirmed in 10 GBM primary cell lines and 2 immortalised cell lines U251 and U87MG. Furthermore, the protein expression of PDL-1, IDO activity and TGF-beta2 secretion were found on most of the untreated GBM primary cell lines. Remarkably, treatment with IFN-gamma increased the PDL-1 cell surface expression and the IDO activity, but reduced the TGF-beta2 secretion of GBM cell lines. We finally analysed the immunosuppressive effects of IDO, PDL-1 and TGF-beta1-3 by measuring IFN-gamma production and cell cytotoxicity activity of tumour antigen-specific T cells. PDL-1 partially affected the IFN-gamma production of antigen-specific T cells in response to GBM primary cell lines, and IDO inhibited lymphocyte proliferation induced by lectins. None of these molecules directly affected the T cell cytotoxicity function. Due to the functional role of PDL-1 and IDO molecules expressed by GBM cells, one could expect that blocking these molecules in the immunotherapy strategies would reinforce the efficiency of these treatments of GBM patients.

show abstract

“…In this regard, recent studies on inflammatory cytokine levels in brain tumors showed persistence of increased cytokine levels during follow up, thus favoring mounting of inflammatory response during postoperative period. [ 34 ] However, the rise in L-fucose in brain tumors suggests that it may be used as a general marker in addition to other markers for brain tumors but it may not be useful for the monitoring of prognosis in brain tumors.…”

Section: Discussionmentioning

confidence: 99%

Assessment of serum L-fucose in brain tumor cases

Shantaram

Monteiro

Aroor

et al. 2010

Ann Indian Acad Neurol

View full text Add to dashboard Cite

Background:Glycosylation of altered tumor cell in relation to cellular heterogeneity in human intracranial tumors remains relatively unexposed. Serum protein-bound carbohydrate, L-Fucose is reported to be overexpressed during tumor progression by many investigators. Therefore, there is a need to determine the diagnostic, prognostic, functional significance of glycoprotein elevations in various cases of tumors.Objective:The objective of the present study was to evaluate the clinical utility of serum L-fucose in patients with brain tumor.Materials and Methods:Serum glyco-conjugate levels were estimated in 99 patients with brain tumors. Estimation of L-fucose was carried out colorimetrically by the method of Winzler using cysteine hydrochloride.Results:There was a significant increase in L-fucose level in most of the patients. In the posttreatment cases, the L-fucose levels were apparently low compared to preoperative values.Conclusion:Our results showed that the rise in serum L-fucose may be used as a general marker for brain tumors in addition to other markers.

show abstract

Cytokine regulation of immune response in patients with a brain tumor or injury

Cited by 5 publications

References 0 publications

Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy

Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions

Assessment of serum L-fucose in brain tumor cases

Contact Info

Product

Resources

About